Paxlovid (nirmatrelvir-ritonavir) is efficient at stopping hospitalization and demise from COVID-19, however few folks use it. An article by SteelFisher et al. (2024) surveyed 1,430 American adults to search out out why. Their analysis discovered that sufferers had been unaware of the remedy and that there was misinformation in regards to the remedy (amongst those that had been conscious). Particularly:

A majority of respondents (85 p.c) had little or no information of Paxlovid, together with 31 p.c who had by no means heard of it. Even amongst those that had been conscious of the drug, many had misconceptions about its effectiveness (39 p.c), uncomfortable side effects (86 p.c) and required timing (61 p.c) that might result in underuse. Decrease consciousness and misconceptions had been extra frequent amongst medically susceptible and underserved populations who may benefit most from entry to Paxlovid, together with adults who haven’t been vaccinated in opposition to COVID-19, these with decrease ranges of schooling, and Black, Hispanic, or Latino adults .

You possibly can learn the complete article right here.